title: Macrophages-mediated neurotoxic effects of intra-nigral manganese administration are attenuated by minocycline.
abstract: The present study was designed to address the role of macrophages in Mn-induced neurotoxicity and to test the hypothesis that minocycline, a tetracycline derivative, attenuates the biochemical and morphological sequelae of Mn. Mn was unilaterally microinjected into rat nigra followed by systemic minocycline or saline administration 24h later, daily for 3 days. At 72h after the intranigral Mn microinjection, tyrosine hydroxylase immunostaining (TH-IS) was evaluated in the striatum, along with the number of macrophages (as indicated by CD11b immunostaining) in the substantia nigra. Mn significantly reduced striatal TH-IS, and causes an increased macrophage number at the lesion site when compared with the control group. The effects of Mn on striatal TH-IS and the number of macrophages at the lesion site were concentration dependent. Consistent with the stated hypothesis, minocycline significantly reduced the macrophage number in the lesion site and minimized the TH-IS striatal loss induced by Mn. These results indicate that an inflammatory response mediated by macrophages is induced by intranigral Mn microinjection, which is fully attenuated by minocycline treatment, suggesting that suppression of macrophage infiltration provides neuroprotection to dopaminergic neurons.
authors.affiliation: Departamento de Ciências Fisiológicas, CCB, Universidade Estadual de Londrina, Caixa Postal 6001, CEP: 86051-970, Londrina, PR, Brazil. ponza@uel.br
authors.forename: Silvia
authors.initials: S
authors.lastname: Ponzoni
mesh_terms: D000818:Animals; D039481:CD11b Antigen / Q000378:metabolism; D002452:Cell Count / Q000379:methods; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D008264:Macrophages / Q000187:drug effects / Q000502:physiology*; D008297:Male; D008345:Manganese / Q000633:toxicity*; D008911:Minocycline / Q000627:therapeutic use*; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D020258:Neurotoxicity Syndromes / Q000209:etiology* / Q000473:pathology; D051381:Rats; D013378:Substantia Nigra / Q000187:drug effects / Q000473:pathology; D013997:Time Factors; D014131:Trace Elements; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism
chemical_list: D039481:CD11b Antigen; D018696:Neuroprotective Agents; D014131:Trace Elements; D008345:Manganese; D014446:Tyrosine 3-Monooxygenase; D008911:Minocycline